---
title: "Mabwell Moves Non-Registered Shareholders to Digital Corporate Communications"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285408385.md"
description: "Mabwell (Shanghai) Bioscience Co., Ltd. has announced a shift to electronic corporate communications for non-registered shareholders, complying with Hong Kong Listing Rules. Future reports and documents will be available in English and Chinese on the company's website and the Hong Kong Stock Exchange platform, eliminating individual notifications. Shareholders preferring hard copies can request them, but requests will only be valid until the end of the next financial year. This move emphasizes a transition towards digital communications in the biopharmaceutical sector."
datetime: "2026-05-06T14:39:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285408385.md)
  - [en](https://longbridge.com/en/news/285408385.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285408385.md)
---

# Mabwell Moves Non-Registered Shareholders to Digital Corporate Communications

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Mabwell (Shanghai) Bioscience Co., Ltd. Class H ( (HK:2493) ).

Mabwell (Shanghai) Bioscience Co., Ltd. has shifted to electronic dissemination of its corporate communications for non-registered shareholders, in line with Hong Kong Listing Rules. Future reports, meeting notices, circulars and other shareholder documents will be published in both English and Chinese on the company’s website and the Hong Kong Stock Exchange disclosure platform instead of being routinely printed.

The company will no longer send individual notifications when new documents are posted online and is urging shareholders to proactively monitor updates. Non-registered shareholders who still prefer hard copies can submit a request form or contact the H share registrar, but such requests will only remain valid until the end of the following financial year unless renewed, signalling a further push toward digital investor communications and reduced reliance on print materials.

**More about Mabwell (Shanghai) Bioscience Co., Ltd. Class H**

Mabwell (Shanghai) Bioscience Co., Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2493. Operating in the biopharmaceutical sector, the company focuses on developing and commercializing bioscience and biotechnology products for both domestic and international markets.

**Average Trading Volume:** 6,906,072

**Current Market Cap:** HK$16.37B

Learn more about 2493 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [688062.CN](https://longbridge.com/en/quote/688062.CN.md)
- [02493.HK](https://longbridge.com/en/quote/02493.HK.md)

## Related News & Research

- [Mabwell Wins FDA Green Light for First-in-Human Trial of Novel Autoimmune Antibody 9MW5211](https://longbridge.com/en/news/285754749.md)
- [Mabwell Plans Up to RMB 1 Billion Targeted Debt Issue to Reshape Capital Structure](https://longbridge.com/en/news/285408743.md)
- [Besra Gold Announces Notice of Meeting and Mgt Information Circular Proxy Form | BESAF Stock News](https://longbridge.com/en/news/286895351.md)
- [OMNICOM TO PRESENT AT THE J.P. MORGAN GLOBAL TECHNOLOGY, MEDIA AND COMMUNICATIONS CONFERENCE | OMC Stock News](https://longbridge.com/en/news/286281406.md)
- [Brady Corporation declares regular dividend to shareholders | BRC Stock News](https://longbridge.com/en/news/286971911.md)